35.65

0.83% -0.30

After Hours: 35.70 0.05 +0.14%

Newamsterdam Pharma Company Nv (NAMS)

Overview News Price History Financials Why NAMS Down? Discussions Forecast

Newamsterdam Pharma Company Nv stock is traded at $35.65, with a volume of 310.43K. It is down -0.83% in the last 24 hours and down -9.31% over the past month. NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Previous Close:

$35.95

Open:

$35.84

24h Volume:

310.43K

Relative Volume:

0.29

Market Cap:

$4.04B

Revenue:

$14.09M

Net Income/Loss:

$-176.94M

P/E Ratio:

-16.58

EPS:

-2.15

Net Cash Flow:

$-141.24M

1W Performance:

+5.85%

1M Performance:

-9.31%

6M Performance:

+93.75%

1Y Performance:

+37.38%

1-Day Range:

$35.24

$36.16

1-Week Range:

$32.85

$37.00

52-Week Range:

$14.06

$42.00

Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile

Name

Newamsterdam Pharma Company Nv

Sector

Healthcare (1130)

Industry

Biotechnology (631)

Phone

35 206 2971

Address

GOOIMEER 2-35, NARRDEN

Employee

Twitter

Next Earnings Date

Latest SEC Filings

NAMS's Discussions on Twitter

Compare NAMS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NAMS Newamsterdam Pharma Company Nv	35.65	4.08B	14.09M	-176.94M	-141.24M	-2.15
VRTX Vertex Pharmaceuticals Inc	462.99	116.51B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	783.71	82.52B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	400.69	52.67B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	849.95	52.08B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	177.42	37.70B	447.02M	-1.18B	-906.14M	-6.1812

Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-20-25	Resumed	H.C. Wainwright	Buy
Aug-25-25	Initiated	Wells Fargo	Overweight
Jul-17-25	Initiated	Goldman	Neutral
Jun-17-25	Initiated	Citigroup	Buy
Jun-10-25	Initiated	Stifel	Buy
Jun-04-25	Initiated	Cantor Fitzgerald	Overweight
Dec-30-24	Initiated	H.C. Wainwright	Buy
May-15-24	Initiated	TD Cowen	Buy
Mar-14-24	Initiated	Scotiabank	Sector Outperform
Jan-18-24	Initiated	Guggenheim	Buy
Jan-16-24	Initiated	Piper Sandler	Overweight
Oct-30-23	Initiated	RBC Capital Mkts	Outperform

View All

Newamsterdam Pharma Company Nv Stock (NAMS) Latest News

Dec 23, 2025

Is NewAmsterdam Pharma Company NV Equity Warrant a good long term investmentUtilities Sector Analysis & Identify Ideal Buy Points With Precision - earlytimes.in

Dec 23, 2025

Dec 22, 2025

Operating cash flow per share of NewAmsterdam Pharma Company N.V. – SWB:KH6 - TradingView — Track All Markets

Dec 22, 2025

Dec 21, 2025

(NAMS) Volatility Zones as Tactical Triggers - Stock Traders Daily

Dec 21, 2025

Dec 20, 2025

Can NewAmsterdam Pharma Company N.V. Equity Warrant stock outperform in 2025 bull marketMarket Growth Report & Short-Term Trading Alerts - Улправда

Dec 20, 2025

Analyst Downgrade: Will Lee Enterprises Incorporated LE70 stock keep raising dividendsJuly 2025 Big Picture & Precise Buy Zone Identification - moha.gov.vn

Dec 20, 2025

How NewAmsterdam Pharma Company N.V. Equity Warrant stock trades before earningsWeekly Investment Summary & Verified Swing Trading Watchlist - Улправда

Dec 20, 2025

Will NewAmsterdam Pharma Company N.V. stock deliver strong dividend growthEarnings Risk Summary & Detailed Earnings Play Strategies - Улправда

Dec 20, 2025

Can NewAmsterdam Pharma Company N.V. stock beat market expectations this quarterQuarterly Profit Report & Real-Time Volume Spike Alerts - Улправда

Dec 20, 2025

Dec 19, 2025

Aug Selloffs: Can NewAmsterdam Pharma Company N.V. stock beat market expectations this quarterMarket Trend Review & Weekly Watchlist for Consistent Profits - Улправда

Dec 19, 2025

Is NewAmsterdam Pharma Company N.V. stock in correction or buying zone2025 Sector Review & Reliable Breakout Forecasts - Улправда

Dec 19, 2025

Is NewAmsterdam Pharma Company N.V. stock undervalued vs historical averagesJuly 2025 Technicals & Daily Stock Trend Reports - DonanımHaber

Dec 19, 2025

Why NewAmsterdam Pharma Company N.V. Equity Warrant stock attracts high net worth investorsMarket Performance Recap & Expert Curated Trade Ideas - DonanımHaber

Dec 19, 2025

Will NewAmsterdam Pharma Company N.V. stock outperform tech sector in 20252025 Earnings Surprises & Community Trade Idea Sharing - DonanımHaber

Dec 19, 2025

Why NewAmsterdam Pharma Company N.V. stock attracts global investorsOptions Play & Real-Time Sentiment Analysis - DonanımHaber

Dec 19, 2025

Is NewAmsterdam Pharma Company N.V. stock positioned for long term growthJuly 2025 Short Interest & High Return Trade Guides - Улправда

Dec 19, 2025

Dec 18, 2025

Will NewAmsterdam Pharma Company N.V. stock beat EPS estimatesPortfolio Gains Report & Real-Time Stock Entry Alerts - ulpravda.ru

Dec 18, 2025

Dec 17, 2025

NewAmsterdam Pharma (NASDAQ:NAMS) Given New $50.00 Price Target at Stifel Nicolaus - Defense World

Dec 17, 2025

Dec 16, 2025

NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says - MarketBeat

Dec 16, 2025

Dec 15, 2025

Understanding Momentum Shifts in (NAMSW) - Stock Traders Daily

Dec 15, 2025

Dec 14, 2025

Is It Too Late To Consider NewAmsterdam Pharma After Its Strong 2025 Share Price Rally? - Yahoo Finance

Dec 14, 2025

Frazier Life Sciences Management L.P. Has $300.75 Million Stock Position in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat

Dec 14, 2025

Dec 12, 2025